Drug bioavailability, the rate at which the active compound of a drug becomes available at the site of action, is key to the successful development of new drugs. The development of hydrogels, self-assembling polymer-based scaffolds, has rapidly accelerated in recent years because of their potential in the improvement of drug bioavailability.
Drug bioavailability, the rate at which the active compound of a drug becomes available at the site of action, is key to the successful development of new drugs. The development of hydrogels, self-assembling polymer-based scaffolds, has rapidly accelerated in recent years because of their potential in the improvement of drug bioavailability.
Hydrogels can be engineered in a number of ways depending on the desired function. Scientists in Japan1 have recently demonstrated the use of a gelatin based hydrogel for the successful administration of a bio therapeutic anti-cancer compound to colon cancer cell lines, reducing the rate of proliferation and migration.
The scientists encapsulated a bioactive lipid, cyclic phosphatidic acid (cPA), within a gelatine scaffold and observed the effect on the growth of a cell-line derived from colon cancer. Electrospray ionization liquid chromatography–mass spectrometry (ESI–MS) and thin-layer chromatography (TLC) analysed cPA release from the scaffold and the rate of degradation. It was found that encapsulation of the drug within the hydrogel improved the lifetime of the drug post-administration by protecting it from degradation, in addition to allowing the gradual release of the drug.
1. Tamotsu Tsukahara and K Murakami-Murofushi, Nature Scientific Reports,2(687), (2012).
This story originally appeared in The Column. Click here to view that issue.
Using GC to Investigate Nerve Agent Presence on Indoor Surfaces
October 28th 2024LCGC International recently spoke to Tomáš Rozsypal of the Nuclear, Biological and Chemical Defence Institute of the University of Defence (Vyskov, Czech Republic) about his work utilizing gas chromatography in researching the persistence of A-234 nerve agent on indoor surfaces, and the paper that resulted from it.
Inside the Lab of the Future (November 2024)
October 28th 2024Drive growth by establishing integrated, AI-fueled lab systems and a data-driven corporate culture that’s ready and resilient, no matter what business challenges emerge tomorrow. Evolving to a Lab of the Future takes the right technologies, systems, and expert guidance.
A Guide to Software-as-a-Service LIMS (November 2024)
October 28th 2024A subscription-based Laboratory Information Management System (LIMS), hosted in the cloud and delivered via the Internet, is a secure, scalable, and cost-effective alternative to traditional software licensing, installation, maintenance, validation, and management. Here’s what you need to know to determine if the software-as-a-service (SaaS) delivery model for a LIMS is right for your organization.